Today: 4 June 2026
Browse Category

NASDAQ:HCWB 15 May 2026 - 20 May 2026

HCW Biologics Jumps, Doubles Again as Traders Pile Into Biotech Name

HCW Biologics Jumps, Doubles Again as Traders Pile Into Biotech Name

HCW Biologics shares surged 122% to $2.35 Wednesday, trading as high as $3.96 on heavy volume after a new securities filing and recent earnings. The company is seeking up to $5.6 million in a stock or warrant offering to fund development of its IL-2 fusion protein, HCW9302. First-quarter revenue rose to $6.54 million, mainly from a licensing deal with Beijing Trimmune Biotech.
20 May 2026
·
HCW Biologics jumps 262% after Trimmune deal, Q1 profit, Nasdaq risk update

HCW Biologics jumps 262% after Trimmune deal, Q1 profit, Nasdaq risk update

HCW Biologics shares jumped 262% to $1.22 Friday after the company posted a $3.47 million first-quarter profit, driven by a $6.5 million licensing deal with Beijing Trimmune Biotech. The company faces a possible Nasdaq delisting and will ask shareholders to approve a reverse stock split on June 15. HCW plans to report early Phase 1 data for its alopecia drug in the first half of 2026.
16 May 2026
·
HCW Biologics Stock News: Profit, Pipeline and Nasdaq Risk Put HCWB Back in Focus

HCW Biologics Stock News: Profit, Pipeline and Nasdaq Risk Put HCWB Back in Focus

HCW Biologics posted first-quarter net income of $3.47 million on $6.54 million in revenue, reversing a year-earlier loss, after a licensing deal with Beijing-based Trimmune Biotech. The company remains below Nasdaq’s $1 minimum bid and awaits early human data from its lead autoimmune drug, HCW9302, in alopecia areata. HCW also reported positive animal study results for a lung drug targeting premature infants.
15 May 2026
·

Stock Market Today

  • LanzaTech JV Raises $75 Million in Hong Kong IPO, Shares Surge
    June 4, 2026, 2:26 PM EDT. LanzaTech Global's joint venture Beijing Shougang LanzaTech raised about $75 million through an initial public offering on the Hong Kong Stock Exchange. The company sold 40 million H-shares at roughly $1.86 per share, valuing the venture near $750 million. LanzaTech's stake adjusted to 8.38% post-IPO. The venture operates four commercial plants using LanzaTech's carbon recycling technology, reporting revenue between $77 million and $87 million from 2023 to 2025. Nasdaq-listed LanzaTech shares jumped over 26% to $6.90 following the listing, reflecting strong investor interest in sustainable fuel solutions.

Latest articles

Grab Stock Bounces While Nasdaq Sags—What Traders Are Waiting For Next

Grab Stock Bounces While Nasdaq Sags—What Traders Are Waiting For Next

4 June 2026
Grab Holdings’ U.S. shares jumped 2.9% to $3.51 as investors weighed strong Q1 results—revenue up 24% to $955 million, adjusted EBITDA up 46% to $154 million—and the consolidation of Indonesia’s Superbank, now majority-owned by Grab, against risks from higher fuel costs and regional regulation, leaving the stock sensitive to further updates on profitability and fintech growth.
Goldman Sachs Jumps as Dow Sets New High

Goldman Sachs Jumps as Dow Sets New High

4 June 2026
Goldman Sachs shares surged 4.6% to $1,095.89, powering the Dow to an all-time high as investors rotated into financials; the move was amplified by Goldman’s high share price in the price-weighted Dow, while the bank’s lead role in the $75 billion SpaceX IPO and strong Q1 earnings added momentum, even as analysts flagged risks from high IPO valuations and geopolitical uncertainty.
Celsius Drops in New York After Texas Inquiry Hits Alani Nu Play

Celsius Drops in New York After Texas Inquiry Hits Alani Nu Play

4 June 2026
Celsius shares plunged 6.8% to near a 52-week low after Texas opened a probe into whether its Alani Nu drinks misled consumers about safety for minors, raising fresh legal and consumer-safety concerns just as the company relies on Alani Nu for growth and integration with PepsiCo’s distribution system.
Veru shares jump after Novo Nordisk deal draws traders

Veru shares jump after Novo Nordisk deal draws traders

4 June 2026
Veru shares soared 112% to $4.78 after announcing Novo Nordisk will supply Wegovy at no charge for Veru’s Phase 2b obesity trial, with Veru retaining global rights to enobosarm but granting Novo a right of first negotiation; analysts called the deal a “significant event” and kept $24–$25 targets, while Veru warned trial risks and reimbursement challenges remain.
CRISPR Therapeutics Jumps 12% in New York Trading

CRISPR Therapeutics Jumps 12% in New York Trading

4 June 2026
CRISPR Therapeutics shares soared 11.7% to $58.15 after presenting at the Jefferies Global Healthcare Conference, with sector momentum lifting gene-editing stocks and the SPDR S&P Biotech ETF up 3.0%. Casgevy, its key sickle cell therapy, posted $43 million Q1 revenue, but a $122.9 million net loss and biotech risks mean the rally hinges on investor appetite and upcoming clinical updates.
Go toTop